Study of FoxA Pioneer Factor at Silent Genes Reveals Rfx-Repressed Enhancer at Cdx2 and a Potential Indicator of Esophageal Adenocarcinoma Development
2011

Study of FoxA Factor at Silent Genes and Its Role in Esophageal Cancer

Sample size: 42 publication 10 minutes Evidence: high

Author Information

Author(s): Watts Jason A., Zhang Chaolin, Klein-Szanto Andres J., Kormish Jay D., Fu Jian, Zhang Michael Q., Zaret Kenneth S.

Primary Institution: University of Pennsylvania School of Medicine

Hypothesis

Understanding how silent genes can be competent for activation provides insight into development and cancer progression.

Conclusion

The study suggests that decreased expression of Rfx1 could indicate progression from Barrett's esophagus to esophageal adenocarcinoma.

Supporting Evidence

  • FoxA transcription factors are known as pioneer factors that can engage silent genes.
  • Rfx1 expression decreases during the progression to esophageal adenocarcinoma.
  • Mutations in the Rfx1 site increase enhancer activity, suggesting its repressive role.

Takeaway

The researchers found that a protein called Rfx1 helps keep certain genes silent, and when Rfx1 levels drop, it might lead to cancer in the esophagus.

Methodology

The study involved genomic location analysis of the FoxA transcription factor in mouse liver and human esophageal tissues, along with ChIP-qPCR and luciferase assays.

Potential Biases

Potential bias in sample selection and the interpretation of immunohistochemistry results.

Limitations

The study primarily focuses on a specific set of genes and may not generalize to all silent genes or other tissues.

Participant Demographics

The study included anonymized patient-derived samples from various stages of esophageal conditions.

Statistical Information

P-Value

p≤0.0001

Statistical Significance

p≤0.0001

Digital Object Identifier (DOI)

10.1371/journal.pgen.1002277

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication